Promis Diagnostics was founded with the vision of enabling patients to lead healthier lives by providing actionable and affordable options for cancer screening and diagnostics.
Our specialization is in discovering biomarkers and developing highly specific detection methods. We develop and commercialize diagnostic tests for the early detection of cancer to improve patient outcomes. Promis Diagnostics operates a state-of-the-art CLIA-certified molecular laboratory providing cancer diagnostics. We are currently preparing for commercialization of our innovative cancer diagnostic tests for better detection and assisting in the prevention and monitoring of cancer.
Methylation Biomarker Discovery Engine
Aberrant methylation can inactivate tumor suppressors and DNA repair genes and it has been demonstrated to be an early event in the development of human cancers. Thus, DNA methylation changes in tumor tissues and body fluids such as blood, stool or urine have emerged as a highly promising biomarker for cancer screening and diagnosis.
Proprietary Methylation Markers
Our tests are based on proprietary epigenetic and other molecular technologies. We have identified proprietary methylation markers for several cancers. We have successfully performed validation studies on clinical samples including colorectal cancer, Bladder and lung cancer.
Linear Target Enrichment-Quantitative Methylation-Specific PCR
Our portfolio of diagnostic molecular assays are built on our patented technology (LTE-qMSP) for the selective amplification and measurement of methylated DNA biomarkers. These tests maintain a high sensitivity and specificity rate even when the markers exist in minute amounts within liquid biopsy samples. We are using this technology in our range of early cancer detection products which include colorectal, bladder, and lung cancer.